This issue we are discussing several important topics in molecular imaging and medicine. One addresses the need for developing tools not only to monitor therapeutic responses, but also to stratify patients into the treatments that are most likely to result in significant responses. This concept can be applied not only to oncology, but also is highly relevant in patients with neurologic and cardiac diseases.

This issue features several topics of critical importance in the field of imaging.

Published research on contrast medium-induced nephropathy (CIN) has been unable to detect an increased incidence of acute kidney injury (AKI) in patients exposed to intravenous contrast during an imaging examination compared with unexposed patients, according to a meta-analysis published Jan. 14 online in Radiology.

Check out the most popular educational sessions, expert blogs and much more. 

Florbetapir could change how dementia is diagnosed, but it may be hampered by practice management and clinical challenges.

Researchers are exploring the diagnostic potential of functional MRI in behavioral disorders 

The National Institutes of Health (NIH) has launched the Parkinson’s Disease Biomarkers Program, which aims to accelerate the search for biomarkers in Parkinson's disease, in part by improving collaboration among researchers and helping patients get involved in clinical studies.

Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for PET imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment.